HIV prevalence at reception into Australian prisons, 1991-1997.
OBJECTIVE
To measure the extent and outcome of HIV antibody testing at reception into Australian prisons.


METHODS
Cross-sectional survey at reception into prison.


METHODS
People received into Australian prisons from 1991 to 1997.


METHODS
Number of people tested for HIV infection and prevalence of diagnosed HIV infection.


RESULTS
In 1991-1997, HIV antibody testing was carried out for 72% of prison entrants in Australia; the percentage tested declined significantly from 76% in 1991 to 67% in 1997 (P < 0.001). In New South Wales, the percentage of entrants tested at reception into prison dropped from almost 100% in 1991-1994 to 45% in 1997, whereas in the Northern Territory, South Australia and Western Australia the extent of testing increased significantly (P < 0.001). HIV prevalence was 0.2% among people received into Australian prisons in 1991-1997, and did not differ by sex. Most people with HIV infection (242/378; 64%) received into prison in 1991-1997 had been diagnosed at a previous entry; 136 people (36% of the total number of diagnoses) were newly diagnosed at reception into prison.


CONCLUSIONS
A national monitoring system in place from 1991 indicates generally high rates of HIV antibody testing and a low prevalence of HIV infection among people entering Australian prisons. In each year, people not previously known to the prison health service to have HIV infection were received into prison, indicating continuing HIV infection in the population entering Australian prisons.
McDonald
A M
AM
National Centre in HIV Epidemiology and Clinical Research, Sydney, NSW. amcdonald@nchecr.unsw.edu.au
Ryan
J W
JW
Brown
P R
PR
Manners
C J
CJ
Falconer
A D
AD
Kinnear
R C
RC
Harvey
W J
WJ
Hearne
P R
PR
Banaszczyk
M
M
Kaldor
J M
JM
D001315:Australia; D003430:Cross-Sectional Studies; D005260:Female; D015658:HIV Infections / Q000453:epidemiology*; D006526:Hepatitis C / Q000150:complications; D006801:Humans; D008297:Male; D011330:Prisons; D015819:Substance Abuse, Intravenous / Q000150:complications